Crohn's disease, The Lancet, vol.380, issue.9853, pp.1590-605, 2012. ,
DOI : 10.1016/S0140-6736(12)60026-9
Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases, Pharmacology & Therapeutics, vol.159, pp.110-119, 2016. ,
DOI : 10.1016/j.pharmthera.2016.01.001
Determinants of health-related quality of life in Crohn's disease: A systematic review and meta-analysis, Journal of Crohn's and Colitis, vol.8, issue.2, pp.93-106, 2014. ,
DOI : 10.1016/j.crohns.2013.04.007
The Natural History of Adult Crohn's Disease in Population-Based Cohorts, The American Journal of Gastroenterology, vol.132, issue.2, pp.289-97, 2010. ,
DOI : 10.1053/j.gastro.2008.09.053
Indirect health costs in ulcerative colitis and Crohn???s disease: a systematic review and meta-analysis, Expert Review of Pharmacoeconomics & Outcomes Research, vol.24, issue.2, pp.253-266, 2015. ,
DOI : 10.3748/wjg.14.6641
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review, Gastroenterology, vol.142, issue.1, pp.46-54, 2012. ,
DOI : 10.1053/j.gastro.2011.10.001
GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for Ulcerative Colitis, N Engl J Med, vol.369, issue.8, pp.699-710, 2013. ,
GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease, N Engl J Med, vol.22, issue.8, pp.369711-369732, 2013. ,
Effects of Vedolizumab Induction Therapy for Patients With Crohn???s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed, Gastroenterology, vol.147, issue.3, pp.618-627, 2014. ,
DOI : 10.1053/j.gastro.2014.05.008
The Real-World Effectiveness and Safety of Vedolizumab for Moderate???Severe Crohn???s Disease: Results From the US VICTORY Consortium, The American Journal of Gastroenterology, vol.4, issue.8, pp.1147-55, 2016. ,
DOI : 10.1016/j.crohns.2010.05.011
Effectiveness and Safety of Vedolizumab Induction Therapy for??Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.14, issue.11, pp.1593-1601, 2016. ,
DOI : 10.1016/j.cgh.2016.02.016
URL : https://hal.archives-ouvertes.fr/hal-01278611
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months, Clinical Gastroenterology and Hepatology, vol.15, issue.11, pp.1542-356531121, 2016. ,
DOI : 10.1016/j.cgh.2016.11.023
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease, Alimentary Pharmacology & Therapeutics, vol.41, issue.Suppl. 1, pp.188-202, 2015. ,
DOI : 10.1002/jcph.240
Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis, Inflammatory Bowel Diseases, vol.23, issue.8, pp.1272-1277, 2017. ,
DOI : 10.1097/MIB.0000000000001211
Predictors of response to infliximab in luminal Crohn's disease, Gastroent??rologie Clinique et Biologique, vol.29, issue.2, pp.145-154, 2005. ,
DOI : 10.1016/S0399-8320(05)80718-3
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease, The American Journal of Gastroenterology, vol.35, issue.9, pp.2357-63, 2002. ,
DOI : 10.1046/j.1365-2567.2000.00079.x
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.117, issue.12, pp.1451-1458, 200315. ,
DOI : 10.1111/j.1572-0241.2002.05784.x
Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?, Gut, vol.257, issue.(1), pp.362-381, 2017. ,
DOI : 10.1097/SLA.0b013e31827d99a2
Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project, Gut, vol.58, issue.Suppl 04, pp.1556-65, 2013. ,
DOI : 10.1136/gut.2007.144865
Tu1350 Vedolizumab in the Treatment of IBD: The University of Chicago Experience, Gastroenterology, vol.148, issue.4, p.866, 2015. ,
DOI : 10.1016/S0016-5085(15)32937-1
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006. ,
DOI : 10.1136/gut.2005.082909
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY, The Lancet, vol.315, issue.8167, p.514, 1980. ,
DOI : 10.1016/S0140-6736(80)92767-1
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions, Clinical Gastroenterology and Hepatology, vol.14, issue.3, pp.348-354, 2016. ,
DOI : 10.1016/j.cgh.2015.06.001
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, The American Journal of Gastroenterology, vol.107, issue.9, pp.1324-1338, 2015. ,
DOI : 10.1038/ajg.2012.117
URL : https://hal.archives-ouvertes.fr/hal-01191653
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis, Gastroenterology, vol.147, issue.6, pp.1296-1307, 2014. ,
DOI : 10.1053/j.gastro.2014.08.035
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-2476, 2005. ,
DOI : 10.1056/NEJMoa050516
Correlation Between the Crohn's Disease Activity and Harvey???Bradshaw Indices in Assessing Crohn's Disease Severity, Clinical Gastroenterology and Hepatology, vol.8, issue.4, pp.357-63, 2010. ,
DOI : 10.1016/j.cgh.2010.01.001
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006. ,
DOI : 10.1136/gut.2005.082909
French national consensus clinical guidelines for the management of Crohn???s disease, Digestive and Liver Disease, vol.49, issue.4, pp.368-377, 2017. ,
DOI : 10.1016/j.dld.2016.12.008
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study, Alimentary Pharmacology & Therapeutics, vol.66, issue.618-627, pp.310-321, 2017. ,
DOI : 10.1136/gutjnl-2015-311079
Effects of Vedolizumab Induction Therapy for Patients With Crohn???s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed, Gastroenterology, vol.147, issue.3, pp.618-627, 2014. ,
DOI : 10.1053/j.gastro.2014.05.008
Clinical implications of mucosal healing for the management of IBD, Nature Reviews Gastroenterology & Hepatology, vol.50, issue.1, pp.15-29, 2010. ,
DOI : 10.1111/j.1572-0241.2005.41992.x
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study, Alimentary Pharmacology & Therapeutics, vol.60, issue.Suppl. A, pp.1090-102, 2016. ,
DOI : 10.1136/gut.2010.226548
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients, Inflammatory Bowel Diseases, vol.21, issue.12, pp.2879-85, 2015. ,
DOI : 10.1097/MIB.0000000000000561
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease???the Israeli Real-World Experience, Inflammatory Bowel Diseases, vol.23, issue.3, pp.404-408, 2017. ,
DOI : 10.1097/MIB.0000000000001039
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres, Frontline Gastroenterology, vol.110, issue.3, pp.196-202, 2017. ,
DOI : 10.1136/flgastro-2016-100720
The ??4??1 Homing Pathway is Essential for Ileal Homing of Crohn's Disease Effector T Cells in vivo, Gastroenterology, vol.152, issue.5, pp.379-391, 2017. ,
DOI : 10.1016/S0016-5085(17)30841-7
Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases, Cell Host & Microbe, vol.21, issue.5, pp.603-610, 2017. ,
DOI : 10.1016/j.chom.2017.04.010
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study, Alimentary Pharmacology & Therapeutics, vol.21, issue.Suppl. 1, pp.11-121199, 2016. ,
DOI : 10.1097/MIB.0000000000000273
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-1395, 2010. ,
DOI : 10.1056/NEJMoa0904492
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis, Gastroenterology, vol.146, issue.2, pp.392-400, 2014. ,
DOI : 10.1053/j.gastro.2013.10.052
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti???Tumor Necrosis Factor Therapy for Crohn???s Disease: A Meta-analysis of Placebo-controlled Trials, Clinical Gastroenterology and Hepatology, vol.13, issue.13, pp.2233-2273, 2015. ,
DOI : 10.1016/j.cgh.2015.06.034
Predictors of Clinical Response and Remission at 1??Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab, Digestive Diseases and Sciences, vol.15, issue.6, pp.1590-1596, 2017. ,
DOI : 10.1002/ibd.20918
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population, Clinical Gastroenterology and Hepatology, vol.10, issue.9, pp.1002-1009, 2012. ,
DOI : 10.1016/j.cgh.2012.02.004